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Abstract. Two different series of oligonucleotide-peptide conjugates have been 
efficiently synthesized by stepwise solid-phase synthesis. First, oligonucleotides and 
oligonucleotide phosphorothiotes containing polar groups at the 3’-termini, such as amine 
and guanidinium groups were prepared. ODNs conjugates carrying several lysine 
residues were obtained directly from Fmoc deprotection whereas ODN conjugates with 
guanidinium groups were obtained by post-synthetic guanidinylation. The second family 
contains different urea moieties that were achieved by standard protocols. All products 
were fully characterized by reversed phase HPLC and MALDI-TOF mass spectrometry 
yielding satisfactory results. Oligonucleotide phosphorothioate conjugates were evaluated 
as potential antisense oligonucleotides in the inhibition of the luciferase gene. 
 
The use of modified oligonucleotides (ODNs) as potential therapeutics has 
emerged in the last few years with the antisense and gene-silencing technologies as the 
most important applications.1 However, the low stability of these ODNs against 
exonucleases and endonucleases along with their poor cellular uptake properties (as a 
result of oligonucleotide size and the repulsion of the negatively charged phosphate 
backbone) have turned into a real bottleneck in the use of these compounds as clinical 
drugs.2 Many attempts to change these limitations have been made including the 
substitution of the aforementioned phosphate internucleotide bond with phosphorothioate 
groups3 or the conjugation of cationic lipophilic carriers,4 polymers or nanoparticles5 
with ODNs thereby improving their ability to transverse cell membranes. 
 
Recently, the use of synthetic transporters mimicking cell-penetrating peptides 
(CPPs)6 has become a powerful method for transporting materials across the cell 
membrane,7 especially nucleic acids (e.g. short interfering RNAs (siRNAs),8 aptamers9 
and antisense oligonucleotides (ASO)10). Taking this into account, our research group has 
become interested in the preparation of ODNs carrying CPPs for gene silencing.11 From a 
synthetic point of view, there are two different strategies for obtaining ODN-peptide 
conjugates: (1) the non-covalent approach, where amphipathic peptides can condense 
with DNA molecules, and (2) the covalent approach, which involves formation of a 
covalent conjugate between the cargo and the peptide. These strategies have recently 
been covered in several reviews.12 
 
In addition to the use of CPPs as internalization agents, the introduction of 
additional groups into the CPPs may help to increase the cellular uptake of the 
corresponding ODN-CPP conjugates. For instance, it is known that the guanidinium 
group (pka = 12.5) plays an important role in several biological processes due to its 
highly basic and positively charged character over a wide pH range.13 This moiety has 
been incorporated onto different positions of ODN-CPP conjugates such as the 
nucleobase,14 the 2’-position of the sugar ring13c,15 and the phosphate internucleotide 
bond.16  Interestingly, CPP containing guanidinium moieties (arginine octamer, R8)17 and 
oligonucleotide-arginine conjugates (such as siRNAs18 and ASO19 derivatives) have 
shown promising results in cell delivery.  
 
However, only non-covalent synthetic approaches or solution-phase conjugations 
(somewhat limited due to its high cost and time consuming processes) have been reported, 
making total stepwise solid-phase synthesis20 a possible alternative for obtaining such 
conjugates. 
 
We have therefore explored the possibility of synthesizing ODN-CPP conjugates 
containing two, four and eight amine and guanidinium moieties (ODN-(lysine)n and 
ODN-(homoarginine)n derivatives; Figure 1) following a stepwise solid-phase approach. 
Moreover, we have focused on the stepwise synthesis of another family of ODN-CPP 
conjugates carrying different lipophilic urea moieties (e.g. aliphatic and aromatic units; 
Figure 1). Finally, this synthetic strategy has been used to synthesize oligonucleotide 
phosphorothioate derivatives designed to inhibit the Renilla luciferase gene21 and 
carrying the aforementioned modifications (lysines, homoarginines and ureas). The novel 
oligonucleotide phosphorothioate derivatives have been evaluated in cells and their 
antisense activities have been compared to the respective control antisense ODN. 
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Figure 1. ODN-CPP conjugates synthesized by the stepwise solid-phase approach. 
 
Four oligonucleotide sequences were chosen: two phosphodiester sequences (the 
self complementary sequence A (Dickerson-Drew dodecamer) 22 and a single strand 15-
mer of sequence B (see Table 1)) and two phosphorothioate sequences C and D for 
antisense studies. 
 
 
Table 1. Oligodeoxynucleotide sequences  
 
 backbone Sequences (5’-3’) 
A phosphodiester CGCGAATTCGCG 
B phosphodiester TAGAGGGTCCATTGC 
C phosphorothioate AGGTCTTGTTTCCTTTGC 
D phosphorothioate CTGTCTGACGTTCTTTGT 
 
First, we focused on the solid-phase synthesis of oligonucleotide phosphodiester-
lysine conjugates (4a-f; Figure 2). The synthesis of the conjugates 4a-f (ODN-Lysine)n (n 
= 2, 4 and 8) started with the assembly of the peptide sequences. Incorporation of two, 
four and eight lysine units in the resin was carried out using the stepwise approach23 and 
standard “Boc-chemistry” protocols.  
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Figure 2. Synthesis of solid supports 3a-c, ODN-lysine conjugates (4a-k) and ODN-
homoarginine conjugates (5a-i) 
 
Commercially available poly(ethylene glycol)-polystyrene (PEG-PS, 1) 
(PerSeptive Biosystems, 0.19 mmol/g) was used as our starting material. Before 
introducing the aforementioned lysine units (from commercial available Boc-Lys-tfa-OH 
amino acid, Novabiochem), the solid support 2 was equally divided into three parts. Then, 
the respective peptides (formed by two, four and eight lysine units, respectively) were 
synthesized. The last Boc group was removed (under acidic conditions) after completing 
the peptide sequence. The resulting free amine was protected with 4-(trityloxy)butanoic 
acid24 to give the respective solid supports 3a, 3b and 3c. The modified supports were 
then employed in the preparation of ODN strands using a DNA synthesizer. In all cases, 
coupling yields were around 95% by the analysis of the DMT group released in each step. 
After cleaving the resins with ammonia solution (32%) at 55 ºC overnight, the 
corresponding modified ODN-peptide conjugates in their NH2 form were purified by 
DMT on based protocols to give our expected lysine conjugates (ODN-Lysine) 4a–f. 
These conjugates were analyzed by analytical HPLC and confirmed by MALDI-TOF 
mass spectrometry (MS) (Table 2). 
 
We then incorporated the guanidinium groups into the conjugates 4a-f using the 
post-synthetic approach (Figure 2). The guanidinylation reaction was carried out using a 
modified version of the method described in the literature16a,b (55 ºC, overnight). In all 
reactions, selective and quantitative guanidinylation was observed. After desalting 
(Sephadex G-25), the guanidinylated-ODN-CPPs (ODN-HArg) 5a-f were analyzed by 
analytical HPLC and confirmed by MALDI-TOF mass spectrometry (Table 2). 
 
Having in hand ODN-lysine and ODN-homoarginine conjugates 4-5, we focused 
on the solid-phase synthesis of oligonucleotide-lysine-urea conjugates (Figure 3). In 
order to increase the lipophilic character of such conjugates, aliphatic and aromatic urea 
moieties were chosen. In general, ureas have been synthesized on solid-support by 
several strategies:25 The most common approaches involve the reaction of a polymer-
supported amine with isocyanates26 or active carbamates.27 Here, we follow the method 
described by Kennan et al., which involves the use of p-nitrophenylchloroformiate 
(pNPC) as activating group.27 
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Figure 3. Synthesis of ODN-lysine-urea conjugates 9a-f 
 
First, we functionalized the solid support with a Fmoc protected sarcosine (Fmoc-
Sar-OH, Bachem). After deprotection of the amino group, the spacer and protected lysine 
(Boc-Lys-Fmoc-OH, Bachem) units were incorporated to the functionalized resin (as 
described above) to give compound 6 (Figure 3). After removing the Fmoc group from 
resin 6, two different amines were incorporated: octylamine (a) as an example of an 
aliphatic amine, and 4-octylaniline (b) as an aromatic amine, thereby achieving the 
expected ureas 7a-b attached to the solid support. Then, the appropriate spacer 2 was 
added, according to the literature.23c The resulting solid supports (8a-b) were then 
employed in the preparation of ODN strands using a DNA synthesizer. The same ODN 
sequences A and B were prepared. Coupling yields were around 95%. The solid supports 
were cleaved with ammonia solution (32%), desalted (Sephadex G-25) and the expected 
ODN-lysine-urea conjugates 9a-d were isolated, analyzed using analytical HPLC and 
confirmed by MALDI-TOF mass spectrometry (Table 2). 
 
Next, the effect of the substitutions on the thermal stability of the duplex was 
analyzed by denaturation studies (Table 2).   
 
Table 2. MALDI-TOF mass spectrometry and melting temperatures (ºC) data of ODN-
(lysine)n, ODN-(HArg)n and ODN-lysine-urea conjugates. 
 
 
 Comp. Sequence 3’-modification Tm (∆Tm)a MW (calcd) MW (found) 
4a A (Lys)2 53.0 (8.9) 4154 4157 
4b A (Lys)4 53.4 (9.3) 4415 4427 
4c A (Lys)8 56.2 (12.1) 4931 4932 
4d B (Lys)2 54.7 (0) 5117 5125 
4e B (Lys)4 55.3 (0.6) 5373 5378 
4f B (Lys)8 54.1 (-0.6) 5890 5890 
4g C (Lys)2 33.8 (3.3) 6253 6259 
4h C (Lys)4 33.5 (3.0) 6509 6511 
4i C (Lys)8 33.7 (3.2) 7022 7020 
4j D (Lys)2 n.d. 6253 6280b 
4k D (Lys)8 n.d. 7022 7091c 
5a A (Arg)2 62.0 (17.9) 4240 4251 
5b A (Arg)4 62.4 (18.3) 4587 4583 
5c A (Arg)8 59.3 (15.2) 5275 5274 
5d B (Arg)2 55.4 (0.7) 5203 5202 
5e B (Arg)4 55.2 (0.5) 5545 5545 
5f B (Arg)8 53.3(-1.4) 6234 6214d 
5g C (Arg)2 33.7 (3.2) 6339 6337 
5h C (Arg)4 35.5 (5.0) 6681 6669d 
5i C (Arg)8 32. 8 (2.3) 7366 5894e 
9a A Urea aliph. 59.0 (14.9) 4189 4192 
9b A Urea arom. 58.0 (13.9) 4261 4263 
9c B Urea aliph. 52.1 (-2.6) 5146 5147 
9d B Urea arom. 49.0 (-5.7) 5222 5223 
9ef C Urea aliph. 34.2 (3.7) 6306 6309 
9ff C Urea arom. 31.0 (0.5) 6377 6380 
10a A None 44.1 (0) n.d. n.d. 
10b B None 54.7 (0) n.d. n.d. 
10c C None 30.5 (0) 5769 5725 
10d D None n.d. 5715 5720 
n.d. not determined; a∆Tm is the difference between the melting temperature of the 
modified oligonucleotide minus the melting temperature of the corresponding unmodified 
oligonucleotide; appropriate complementary sequences are unmodified, buffer conditions 
50 mM NaCl, 10 mM sodium phosphate pH 7.0; b[M+Na+]; c[M+K+Na+]; d[M-H20]  ethe 
mass correspond to the removal of the whole peptide and two spacers; fthe linkage 
between the peptide and the peptide was 6-(trityloxy)hexanoic acid. 
 
Compared to the unmodified ODN (10a) having a Dickerson sequence (Tm = 
44.1ºC), the corresponding ODN-peptide conjugates (lysine, homoarginine and urea 
derivatives 4a-c, 5a-c, 9a-b, respectively) had greater duplex stability when hybridized to 
their ODN complement (with ∆Tm in the range of 8.9ºC-12.1ºC for 4a-c, 15.2ºC-17.9ºC 
for 5a-c, and 13.9ºC-14.9ºC for 9a-b). The most stabilizing modifications were the 
homoarginines (5a-c) probably due to electrostatic interaction of the guanidinium groups 
with phosphates. Unexpectedly the urea modifications (9a-b) had higher Tm’s than the 
lysine modified dodecamers (4a-c). At present we have not explanation for this behaviour, 
but we have observed similar results with the same dodecamer carrying other lipids.  
 
When compared to unmodified ODN (10b) having a 15mer sequence (Tm = 
54.7ºC), the corresponding conjugates had similar duplex stability (lysine and 
homoarginine derivatives 4d-f, 5d-f, respectively), or lower (with ∆Tm -2.6ºC and -5.7 
ºC for the aliphatic and aromatic ureas 9c-d, respectively). Based on these results we 
hypothesize that the high Tm values observed for the Dickerson derivatives (4a-c, 5a-c, 
9a-b) may be due to the unique nature of self-complementary / palindromic 
oligonucleotide sequences.28  
 
Since the above experiments showed that ODN-(lysine)n, ODN-(homoarginine)n 
and ODN-lysine-urea conjugates could be effectively synthesized, it was of interest to 
study the potential therapeutic applications of such conjugates. In particular, we 
evaluated the effect of the above described modifications at the 3’ end of oligonucleotide 
strands on the ability of the corresponding conjugate derivatives to act as inhibitors of 
gene expression. Furthermore, we tested the ability of such conjugates to impart cell 
uptake.  
 
First, lysine, homoarginine and lysine-urea residues were incorporated at the 3’ 
end of a phosphorothioate ASO strand that targets the 21-38 site of Renilla luciferase 
mRNA.21 (sequence C). Following the same experimental procedures described in 
Figures 2 and 3, we prepared ASO-peptide conjugates containing two, four and eight 
lysine and homoarginine residues (4g-i and 5g-i, respectively), and one lysine unit 
carrying aliphatic and aromatic urea moieties (9e and 9f, respectively; see Table 2). The 
unmodified phosphorothioate ASO (10c) was also synthesized. Finally the scrambled 
phosphorothioate sequence D was prepared, unmodified (10d) and carrying 2 (4j) and 4 
(4k) lysines. All ASO derivatives were analyzed by analytical HPLC and confirmed by 
MALDI-TOF mass spectrometry (Table 2). Some oligonucleotide phosphorothioate 
conjugates suffer fragmentation during MALDI-TOF spectra acquisition but fragments 
could be identified as the common fragmentations occur at the spacers. Compared to 
unmodified ASO duplex, duplexes containing ASO-lysine, ASO-homoarginine and ASO-
lysine-aliphatic urea conjugates (4g-i, 5g-i, and 9e, respectively) had higher thermal 
stability (with ∆Tm in the range of 3ºC-5ºC), whereas the duplex containing an ASO-
lysine-aromatic urea conjugate (9f) had a similar Tm value (31ºC; unmodified 30.5 ºC, 
Table 2). 
 
After ASO-peptide synthesis we carried out separate gene knockdown 
experiments in SH-SY5Y cells. In a first series of experiments, the cells were 
cotransfected with two luciferase plasmids (Renilla and firefly; target and internal control, 
respectively) and ASO derivatives 10c, 4g-i, 5g-i and 9e-f (60 nM) as well as the 
scrambled sequences (10d, 4j and 4k) by using commercial cationic liposomes 
(Lipofectamine 2000). Twenty-two hours after transfection, the luciferase activities of the 
samples were measured by using a luminometer. The results, showing Renilla luciferase 
activity normalized to firefly luciferase, are shown in Figure 4. Interestingly, lysine, 
homoarginine and lysine-aliphatic urea moieties did not disrupt antisense activity. ASO-
lysine, ASO-homoarginine and ASO-lysine-octylurea conjugates 4g-i (two, four and 
eight lysine residues), 5g-i (two, four and eight homoarginine residues) and 9e, 
respectively, showed activities comparable to the unmodified ASO (10c) (69% 
knockdown of Renilla expression for unmodified 10c versus 61%, 57%, 65%, 64%, 57%, 
66% and 55% for 4g-i, 5g-i and 9e, respectively). Only the urea carrying an aromatic 
group (9f) was detrimental to antisense activity (8% inhibition). However, the results 
obtained for the ASO-lysine (4g-i), ASO-homoarginine (5g-i) and ASO-lysine-aliphatic 
urea (9e) conjugates suggest that, in principle, lysine and homoarginine conjugation does 
not interfere with cellular activity. 
 
 
Figure 4. Plot of gene-specific silencing activities for unmodified (10c), and modified 
(4g-i, 5g-i and 9e-f) antisense oligonucleotides (60 nM per well) targeting the Renilla 
luciferase mRNA expressed in SH-SY5Y cells. Transfection of antisense 
oligonucleotides was carried out by using Lipofectamine 2000. Unmodified (10d) and 
lysine-modified (4j and 4k) scrambled sequences gave no Renilla luciferase inhibition 
(see above and Supplementary Figure S1) 
 
Finally, in a second series of experiments we tested the ability of conjugates 4g-i 
and 5g-i to impart cell uptake. Three hours after transfection of the two luciferase 
plasmids, the cell medium was discarded and the cells were incubated with fresh medium 
and the ASO derivatives in the absence of Lipofectamine 2000 (150, 200 and 300 nM 
ASO-peptide). Twenty-two hours after transfection the luciferase activities were 
measured as described above. Although gene knockdown was significantly less efficient 
than that observed for ASO-peptide-lipofectamine complexes, results (see Supplementary 
Figure S2) showed that all the ASO-peptide conjugates tested were able to penetrate SH 
cells in the absence of a transfection agent (11%, 15%, 11%, 18%, 21%, 28% knockdown 
at 300 nM of Renilla expression for 4g-i and 5g-i, respectively, versus 1.5% for 10c). 
Interestingly the ASO-homoarginine octamer (5i) was able of inducing antisense activity 
at levels of ~28% at 300 nM. 
 
In summary, in this work we have developed a new strategy for the stepwise 
synthesis of ODN-(lysine)n, ODN-(homoarginine)n and ODN-lysine-urea conjugates. 
This method has allowed us to synthesize for first time several ODN covalently linked to 
the homoarginine octamer using a stepwise synthesis protocol. Antisense studies in 
mammalian cells suggest that lysine and homoarginine conjugation does not interfere 
with cellular activity. Moreover, ASO-lysine and ASO-homoarginine conjugates have 
been shown to impart cell uptake. These encouraging results will be followed by more 
detailed cell uptake studies with these and other peptides in order to improve cell delivery 
of ODNs. 
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